ReviewJournal of food and drug analysis2018
Transporter-mediated natural product-drug interactions for the treatment of cardiovascular diseases.
Review in Journal of food and drug analysis, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 35 citations in OpenAlex.
- The fallacy of enzymatic hydrolysis for the determination of bioactive curcumin in plasma samples as an indication of bioavailability: a comparative study.BMC complementary and alternative medicine · 2019Trial
- A single-centre retrospective evaluation of potential drug-drug interactions in breast cancer patients undergoing CDK 4/6 inhibitors chemotherapy.Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners · 2026Article
- Curcumin Between Pleiotropic Potential and Translational Constraints.International journal of molecular sciences · 2026Review
- Repurposing Imeglimin for Chemotherapy-Induced Cognitive Impairment: Targeting Mitochondrial Dysfunction and Neuroinflammation.Cellular and molecular neurobiology · 2026Review
- Modulation of Multispecific Transporters byPharmaceutics · 2024Article
- Challenging directions in pediatric diabetes - the place of oxidative stress and antioxidants in systemic decline.Frontiers in pharmacology · 2024Review
- Whole-Exome Sequencing Revealed New Candidate Genes for Human Dilated Cardiomyopathy.Diagnostics (Basel, Switzerland) · 2022Article
- Metabolism-involved drug interactions with traditional Chinese medicines in cardiovascular diseases.Journal of food and drug analysis · 2022Review
- Folium Sennae Increased the Bioavailability of Methotrexate through Modulation on MRP 2 and BCRP.Pharmaceuticals (Basel, Switzerland) · 2021Article
- Combined Beneficial Effect of Genistein and Atorvastatin on Adipogenesis in 3T3-L1 Adipocytes.Biomolecules · 2021Article
- Disruption of small molecule transporter systems by Transporter-Interfering Chemicals (TICs).FEBS letters · 2020Review
- Description of Druglike Properties of Safranal and Its Chemistry behind Low Oral Exposure.ACS omega · 2020Article
- Herb-Drug Interaction of Red Ginseng Extract and Ginsenoside Rc with Valsartan in Rats.Molecules (Basel, Switzerland) · 2020Article
- Simultaneous determination of cardiovascular drugs in dried blood spot by liquid chromatography-tandem mass spectrometry.Journal of food and drug analysis · 2019Article
- Pharmacokinetic Interactions between Cardiovascular Medicines and Plant Products.Cardiovascular therapeutics · 2019Review
- Resveratrol: A Double-Edged Sword in Health Benefits.Biomedicines · 2018Review
- A regulatory science viewpoint on botanical-drug interactions.Journal of food and drug analysis · 2018Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The growing use of natural products in cardiovascular (CV) patients has been greatly raising the concerns about potential natural product-CV drug interactions. Some of these may lead to unexpected cardiovascular adverse effects and it is, therefore, essential to identify or predict potential natural product-CV drug interactions, and to understand the underlying mechanisms. Drug transporters are important determinants for the pharmacokinetics of drugs and alterations of drug transport has been recognized as one of the major causes of natural product-drug interactions. In last two decades, many CV drugs (e.g., angiotensin II receptor blockers, beta-blockers and statins) have been identified to be substrates and inhibitors of the solute carrier (SLC) transporters and the ATP-binding cassette (ABC) transporters, which are two major transporter superfamilies. Meanwhile, in vitro and in vivo studies indicate that a growing number of natural products showed cardioprotective effects (e.g., gingko biloba, danshen and their active ingredients) are also substrates and inhibitors of drug transporters. Thus, to understand transporter-mediated natural product-CV drug interactions is important and some transporter-mediated interactions have already shown to have clinical relevance. In this review, we review the current knowledge on the role of ABC and SLC transporters in CV therapy, as well as transporter modulation by natural products used in CV diseases and their induced natural product-CV drug interactions through alterations of drug transport. We hope our review will aid in a comprehensive summary of transporter-mediated natural product-CV drug interactions and help public and physicians understand these type of interactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.